C-AMBDSMSbiotech
Small Mobile Stem cells, allogeneic cell therapy, regenerative medicine
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AMBD
C-AMBDC-AMBDSmall Mobile Stem cells, allogeneic cell therapy, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
SMSbiotech Small Mobile Stem cells, allogeneic cell therapy, regenerative medicine
SMSbiotech is a clinical-stage regenerative medicine company founded in 2015 and based in California. The company is developing a proprietary Small Mobile Stem cell therapy platform using adult stem cells derived from human blood. Its lead COPD program has shown early safety and encouraging efficacy signals in Phase 1b and is advancing toward U.S. clinical development and Phase 2.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
SMSbiotech — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic